Summit Therapeutics PLC (FRA:UVF1)
€ 0.2 0 (0%) Market Cap: 65.72 Mil Enterprise Value: -366.59 Mil PE Ratio: 0 PB Ratio: 29.92 GF Score: 14/100

Q2 2024 Summit Therapeutics Inc Earnings Call Transcript

Aug 06, 2024 / 01:00PM GMT
Operator

Good morning and welcome to Summit Therapeutics second-quarter 2024 earnings and update call. (Operator Instructions) Please note that today's call is being recorded.

And at this time, I would like to turn the call over to Dave Gancarz, Summit Therapeutics' Chief Business and Strategy Officer. You may proceed.

Dave Gancarz
Summit Therapeutics Inc - Chief Business and Strategy Officer

Good morning and thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Form 10-Q was also filed earlier this morning and is available on our website. Today's call is being simultaneously webcast, and an archived replay will also be made available later today on our website, www.smmttx.com.

Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer; Dr. Maky Zanganeh, our Chief Executive Officer and President; Manmeet Soni, our Chief Operating Officer and Chief Financial Officer; and Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot